Therapeutic potential of egg yolk antibodies for treating Clostridium difficile infection

Journal of Medical Microbiology

Volumn 60, Issue 8, 2011, Pages 1181-1187

  Mulvey, G L ^a   Dingle, T C ^a   Fang, L ^b   Strecker, J ^a   Armstrong, G D ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b Zyme Fast Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CARBONIC ACID; CWP84 ANTIGEN; FLIC ANTIGEN; FLID ANTIGEN; IMMUNOGLOBULIN Y; POLYHISTIDINE TAG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BINDING AFFINITY; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; ESCHERICHIA COLI; HAMSTER; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOLECULAR CLONING; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFECTIVE AGENTS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CHICKENS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CRICETINAE; EGG YOLK; FEMALE; IMMUNOGLOBULINS;

EID: 79960390376     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.029835-0     Document Type: Article

References (30)

1. Aboudola, S., Kotloff, K. L., Kyne, L., Warny, M., Kelly, E. C., Sougioultzis, S., Giannasca, P. J., Monath, T. P. & Kelly, C. P. (2003). Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 71, 1608-1610.
2. Calabi, E., Ward, S., Wren, B., Paxton, T., Panico, M., Morris, H., Dell, A., Dougan, G. & Fairweather, N. (2001). Molecular characterization of the surface layer proteins from Clostridium difficile. Mol Microbiol 40, 1187-1199.
3. Calabi, E., Calabi, F., Phillips, A. D. & Fairweather, N. F. (2002). Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues. Infect Immun 70, 5770-5778.
4. Giannasca, P. J. & Warny, M. (2004). Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine 22, 848-856.
5. Heap, J. T., Pennington, O. J., Cartman, S. T., Carter, G. P. & Minton, N. P. (2007). The ClosTron: a universal gene knock-out system for the genus Clostridium. J Microbiol Methods 70, 452-464.
6. Heap, J. T., Cartman, S. T., Kuehne, S. A., Cooksley, C. & Minton, N. P. (2010). ClosTron-targeted mutagenesis. Methods Mol Biol 646, 165-182.
7. Hennequin, C., Janoir, C., Barc, M. C., Collignon, A. & Karjalainen, T. (2003). Identification and characterization of a fibronectin-binding protein from Clostridium difficile. Microbiology 149, 2779-2787.
8. Job, M. L. & Jacobs, N. F., Jr (1997). Drug-induced Clostridium difficile-associated disease. Drug Saf 17, 37-46.
9. Karjalainen, T., Barc, M. C., Collignon, A., Trolle ́, S., Boureau, H., Cotte-Laffitte, J. & Bourlioux, P. (1994). Cloning of a genetic determinant from Clostridium difficile involved in adherence to tissue culture cells and mucus. Infect Immun 62, 4347-4355.
10. Karjalainen, T., Waligora-Dupriet, A. J., Cerquetti, M., Spigaglia, P., Maggioni, A., Mauri, P. & Mastrantonio, P. (2001). Molecular and genomic analysis of genes encoding surface-anchored proteins from Clostridium difficile. Infect Immun 69, 3442-3446.
11. Kelly, C. P., Pothoulakis, C., Vavva, F., Castagliuolo, I., Bostwick, E. F., O'Keane, J. C., Keates, S. & LaMont, J. T. (1996). Anti-Clostridium difficile bovine immunoglobulin concentrate inhibits cytotoxicity and enterotoxicity of C. difficile toxins. Antimicrob Agents Chemother 40, 373-379.
12. Kink, J. A. & Williams, J. A. (1998). Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 66, 2018-2025.
13. Kirby, J. M., Ahern, H., Roberts, A. K., Kumar, V., Freeman, Z., Acharya, K. R. & Shone, C. C. (2009). Cwp84, a surface-associated cysteine protease, plays a role in the maturation of the surface layer of Clostridium difficile. J Biol Chem 284, 34666-34673.
14. Ko, K. Y. & Ahn, D. U. (2007). Preparation of immunoglobulin Y from egg yolk using ammonium sulfate precipitation and ion exchange chromatography. Poult Sci 86, 400-407.
15. McFarland, L. V. (2009). Renewed interest in a difficult disease: Clostridium difficile infections - epidemiology and current treatment strategies. Curr Opin Gastroenterol 25, 24-35.
16. Merrigan, M. M., Sambol, S. P., Johnson, S. & Gerding, D. N. (2003). Prevention of fatal Clostridium difficile-associated disease during continuous administration of clindamycin in hamsters. J Infect Dis 188, 1922-1927.
17. Merrigan, M. M., Sambol, S. P., Johnson, S. & Gerding, D. N. (2009). New approach to the management of Clostridium difficile infection: colonisation with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents 33 (Suppl. 1), S46-S50.
18. Monaghan, T., Boswell, T. & Mahida, Y. R. (2009). Recent advances in Clostridiumdifficile-associated disease. Postgrad Med J 85, 152-162.
19. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55-63.
20. Péchiné, S., Gleizes, A., Janoir, C., Gorges-Kergot, R., Barc, M. C., Delmée, M. & Collignon, A. (2005). Immunological properties of surface proteins of Clostridium difficile. J Med Microbiol 54, 193-196.
21. Sambol, S. P., Merrigan, M. M., Tang, J. K., Johnson, S. & Gerding, D. N. (2002). Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 186, 1781-1789.
22. Savariau-Lacomme, M. P., Lebarbier, C., Karjalainen, T., Collignon, A. & Janoir, C. (2003). Transcription and analysis of polymorphism in a cluster of genes encoding surface-associated proteins of Clostridium difficile. J Bacteriol 185, 4461-4470.
23. Tasteyre, A., Barc, M. C., Karjalainen, T., Dodson, P., Hyde, S., Bourlioux, P. & Borriello, P. (2000). A Clostridium difficile gene encoding flagellin. Microbiology 146, 957-966.
24. Tasteyre, A., Barc, M. C., Collignon, A., Boureau, H. & Karjalainen, T. (2001a). Role of FliC and FliD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect Immun 69, 7937-7940.
25. Tasteyre, A., Karjalainen, T., Avesani, V., Delme ́e, M., Collignon, A., Bourlioux, P. & Barc, M. C. (2001). Molecular characterization of fliD gene encoding flagellar cap and its expression among Clostridium difficile isolates from different serogroups. J Clin Microbiol 39, 1178-1183.
26. Voth, D. E. & Ballard, J. D. (2005). Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18, 247-263.
27. Warr, G. W., Magor, K. E. & Higgins, D. A. (1995). IgY: clues to the origins of modern antibodies. Immunol Today 16, 392-398.
28. Weiss, K. (2009). Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents 33, 4-7.
29. Wright, A., Wait, R., Begum, S., Crossett, B., Nagy, J., Brown, K. & Fairweather, N. (2005). Proteomic analysis of cell surface proteins from Clostridium difficile. Proteomics 5, 2443-2452.
30. Wright, A., Drudy, D., Kyne, L., Brown, K. & Fairweather, N. F. (2008). Immunoreactive cell wall proteins of Clostridium difficile identified by human sera. J Med Microbiol 57, 750-756.